These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

781 related articles for article (PubMed ID: 34047762)

  • 41. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.
    van Dam P; Huizing M; Roelant E; Hotterbeekx A; De Winter FHR; Kumar-Singh S; Moons P; Amajoud Z; Vulsteke C; Croes L; Janssens A; Berneman Z; Prenen H; Meuris L; Vanden Berghe W; Smits E; Peeters M
    Eur J Cancer; 2021 May; 148():328-339. PubMed ID: 33773276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
    Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
    Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.
    Ladoire S; Rederstorff E; Goussot V; Parnalland S; Briot N; Ballot E; Truntzer C; Ayati S; Bengrine-Lefevre L; Bremaud N; Coudert B; Desmoulins I; Favier L; Fraisse C; Fumet JD; Hennequin A; Hervieu A; Ilie S; Kaderbhai C; Lagrange A; Martin N; Mazilu I; Mayeur D; Palmier R; Simonet-Lamm AL; Vincent J; Zanetta S; Arnould L; Coutant C; Bertaut A; Ghiringhelli F
    Eur J Cancer; 2022 Apr; 165():13-24. PubMed ID: 35189537
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in staff members of Bandar Abbas Children's Hospital.
    Tariverdi M; Mohammadi H; Hassanzadeh F; Tamaddondar M
    BMC Infect Dis; 2024 Feb; 24(1):253. PubMed ID: 38395759
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Provider Antibody Serology Study of Virus in the Emergency Room (PASSOVER) Study: Special Population COVID-19 Seroprevalence.
    Heyming TW; Sanger T; Tongol A; Schomberg J; Bacon K; Lara B
    West J Emerg Med; 2021 Apr; 22(3):565-571. PubMed ID: 34125028
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Seroprevalence of anti-SARS-CoV-2 IgG among healthcare workers of a large university hospital in Milan, Lombardy, Italy: a cross-sectional study.
    Lombardi A; Mangioni D; Consonni D; Cariani L; Bono P; Cantù AP; Tiso B; Carugno M; Muscatello A; Lunghi G; Pesatori AC; Riboldi L; Ceriotti F; Bandera A; Gori A
    BMJ Open; 2021 Feb; 11(2):e047216. PubMed ID: 33619203
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
    He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
    Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19.
    Qin X; Shen J; Dai E; Li H; Tang G; Zhang L; Hou X; Lu M; Wu X; Duan S; Zhang J; Tsoi MF; Jiang P; Li Y
    BMC Immunol; 2021 Feb; 22(1):14. PubMed ID: 33596826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serologic Surveillance and Phylogenetic Analysis of SARS-CoV-2 Infection Among Hospital Health Care Workers.
    Sikkens JJ; Buis DTP; Peters EJG; Dekker M; Schinkel M; Reijnders TDY; Schuurman AR; de Brabander J; Lavell AHA; Maas JJ; Koopsen J; Han AX; Russell CA; Schinkel J; Jonges M; Matamoros S; Jurriaans S; van Mansfeld R; Wiersinga WJ; Smulders YM; de Jong MD; Bomers MK
    JAMA Netw Open; 2021 Jul; 4(7):e2118554. PubMed ID: 34319354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Seroprevalence of SARS-CoV-2 antibodies among 925 staff members in an urban hospital accepting COVID-19 patients in Osaka prefecture, Japan: A cross-sectional study.
    Nishida T; Iwahashi H; Yamauchi K; Kinoshita N; Okauchi Y; Suzuki N; Inada M; Abe K
    Medicine (Baltimore); 2021 Jun; 100(25):e26433. PubMed ID: 34160433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High SARS-CoV-2 Seroprevalence among Healthcare Workers in Bamako, Mali.
    Somboro AM; Cissoko Y; Camara I; Kodio O; Tolofoudie M; Dembele E; Togo ACG; Ba DM; Sarro YDS; Baya B; Samake S; Diallo IB; Kumar A; Traore M; Kone B; Kone A; Diarra B; Dabitao DK; Wague M; Dabo G; Doumbia S; Holl JL; Murphy RL; Diallo S; Maiga AI; Maiga M; Dao S
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical features and antibody response of patients from a COVID-19 treatment hospital in Wuhan, China.
    Chen Y; Ke Y; Liu X; Wang Z; Jia R; Liu W; Yang C; Jia L; Wang Y; Han L; Xia X; Zhang S; Wang C
    J Med Virol; 2021 May; 93(5):2782-2789. PubMed ID: 33085103
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan.
    Valenti L; Bergna A; Pelusi S; Facciotti F; Lai A; Tarkowski M; Lombardi A; Berzuini A; Caprioli F; Santoro L; Baselli G; Ventura CD; Erba E; Bosari S; Galli M; Zehender G; Prati D;
    Blood Transfus; 2021 May; 19(3):181-189. PubMed ID: 33539289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development, performance evaluation, and clinical application of a Rapid SARS-CoV-2 IgM and IgG Test Kit based on automated fluorescence immunoassay.
    Kang K; Huang L; Ouyang C; Du J; Yang B; Chi Y; He S; Ying L; Chen G; Wang J
    J Med Virol; 2021 May; 93(5):2838-2847. PubMed ID: 33231312
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
    Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
    Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical validation of a second generation anti-SARS-CoV-2 IgG and IgM automated chemiluminescent immunoassay.
    Pieri M; Nuccetelli M; Nicolai E; Sarubbi S; Grelli S; Bernardini S
    J Med Virol; 2021 Apr; 93(4):2523-2528. PubMed ID: 33463719
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine.
    Banga Ndzouboukou JL; Zhang YD; Lei Q; Lin XS; Yao ZJ; Fu H; Yuan LY; Fan XL
    Curr Med Sci; 2021 Dec; 41(6):1081-1086. PubMed ID: 34741251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.